Please provide a data summary for the use of Fibryga in cardiac surgery for use by anesthesia during the procedure as an alternative to cryoprecipitate or IFC in terms of clinical outcomes for differences in factor utilization, cost savings, LOS, time in OR, and bleeding outcomes

Comment by InpharmD Researcher

Based on available data, Fibryga appears comparable to cryoprecipitate for transfusion requirements, mortality, and adverse events in bleeding cardiac surgery patients, although comparative data specific to Fibryga are limited and most pooled estimates reflect multiple fibrinogen concentrates rather than Fibryga alone. Cost findings vary by setting: the FIBRES trial found similar 28-day hospital costs and no meaningful differences in length of stay (LOS) or resource utilization, with cost-effectiveness mainly in noncritically ill and elective subgroups, whereas one small randomized controlled trial showed lower direct costs with Fibryga. Bleeding evidence is mixed, and no reductions in operating room (OR) time or overall factor utilization are established. Of note, no head-to-head trials of Fibryga versus individual fibrinogen concentrate were identified. Overall, the evidence does not establish the superiority of Fibryga over cryoprecipitate or IFC.
Background

The 2021 Society of Thoracic Surgeons (STS), Society of Cardiovascular Anesthesiologists (SCA), American Society of Extracorporeal Technology (AmSECT), and Society for the Advancement of Blood Management (SABM) update to the clinical practice guidelines on patient blood management recommends goal-directed transfusion algorithms incorporating point-of-care (POC) testing, including viscoelastic testing, to reduce periprocedural bleeding and transfusion in cardiac surgical patients (Class I, Level B-R). The guideline notes that POC-based viscoelastic testing algorithms have demonstrated reductions in allogeneic blood product transfusions in high-risk cardiovascular surgery patients. In a large prospective multicenter study involving more than 7,000 cardiac surgery patients, implementation of a viscoelastic testing-based transfusion algorithm in combination with platelet function testing significantly reduced red blood cell and platelet transfusions compared with preimplementation practice. Additionally, several studies incorporating viscoelastic-guided transfusion algorithms have substituted early administration of prohemostatic factor concentrates, including prothrombin complex concentrates (PCCs) and fibrinogen concentrate, for allogeneic blood products, resulting in reduced transfusion requirements. However, the guideline emphasizes that the safety of this approach requires careful evaluation and monitoring of hemostasis. [1]

Meta-analyses and systematic reviews also indicate that POC viscoelastic testing-guided management reduces bleeding and transfusion rates, although a demonstrable reduction in morbidity has not been established. The guideline further notes that viscoelastic testing has been associated with decreased healthcare costs through reductions in transfusion requirements and associated transfusion risks. However, these findings reflect multimodal, goal-directed transfusion strategies rather than the independent effect of fibrinogen concentrate administration. The guideline does not identify Fibryga specifically, provide comparative data between fibrinogen concentrate and cryoprecipitate or other fibrinogen concentrate products, or establish differences in fibrinogen utilization or dosing, total factor product utilization, direct product costs or cost savings, hospital length of stay, operating room time, or specific bleeding outcomes attributable to fibrinogen concentrate. Accordingly, the evidence supports incorporating fibrinogen concentrate into appropriately monitored, viscoelastic-guided blood management protocols as a potential alternative to allogeneic blood products, but does not establish the comparative clinical or economic benefits of Fibryga over cryoprecipitate or other fibrinogen concentrates. [1]

The 2024 European Association for Cardio-Thoracic Surgery (EACTS) and European Association of Cardiothoracic Anaesthesiology and Intensive Care (EACTAIC) guidelines on patient blood management in adult cardiac surgery emphasize fibrinogen supplementation as an important hemostatic intervention in patients experiencing bleeding after cardiac surgery. Endogenous plasma fibrinogen is among the first coagulation factors depleted during significant bleeding and hemodilution, and observational studies have associated lower pre- and postoperative fibrinogen levels with increased bleeding risk. A 2018 meta-analysis of 8 randomized controlled trials (RCTs; N=597) found that fibrinogen concentrate reduced the proportion of patients requiring packed red blood cell (PRBC) transfusions (relative risk [RR] 0.64; 95% confidence interval [CI] 0.49 to 0.83), but did not significantly reduce overall exposure to allogeneic blood products, including PRBCs, platelets, and fresh frozen plasma (FFP; RR 0.79; 95% CI 0.53 to 1.18). Among the included trials, 3 studies (n=128) evaluated preoperative administration of 1–2 g of fibrinogen concentrate, with none demonstrating reduced allogeneic transfusion requirements. Five studies evaluated intraoperative administration of 2-8 g; one compared fibrinogen concentrate with platelet transfusion, while 2 studies (n= 167) using dosing guided by rotational thromboelastometry (ROTEM) or plasma fibrinogen levels reported reductions in allogeneic blood product requirements. However, 2 other RCTs (n= 272) involving patients with bleeding after complex cardiac surgery found no significant benefit in bleeding volume or blood product transfusion requirements. A post hoc analysis further found that increasing fibrinogen levels beyond 2.87 g/L or maximum clot firmness of 14 mm on FIBTEM did not provide additional reductions in bleeding. The meta-analysis did not demonstrate reductions in mortality, reoperation, stroke, myocardial infarction, or thromboembolic events, although the small number of adverse events limited conclusions regarding safety. [2]

Regarding comparisons with cryoprecipitate, a large RCT involving 735 patients with clinically significant bleeding and hypofibrinogenemia following cardiac surgery found that 4 g of fibrinogen concentrate was non-inferior to 10 units of cryoprecipitate in terms of the number of blood components transfused within 24 hours postoperatively, suggesting comparable efficacy for reducing subsequent transfusion requirements (see Table 1). The guidelines therefore support considering fibrinogen supplementation in patients with persistent microvascular bleeding and confirmed hypofibrinogenemia (fibrinogen level <1.5 g/L or an equivalent viscoelastic testing result) to reduce postoperative bleeding and transfusion requirements (Class IIa, Level B). Routine prophylactic fibrinogen administration is not recommended (Class III, Level A). Although these findings support fibrinogen concentrate as an alternative to cryoprecipitate for targeted treatment of acquired hypofibrinogenemia, the guidelines do not identify Fibryga specifically or establish differences between individual fibrinogen concentrate formulations. Additionally, comparative data demonstrating reductions in total coagulation factor utilization, product costs, hospital length of stay (LOS), or operating room time with fibrinogen concentrate versus cryoprecipitate or other fibrinogen concentrates are not provided. Importantly, the comparative cryoprecipitate trial evaluated postoperative transfusion requirements rather than intraoperative outcomes during cardiac surgery, and its findings should not be interpreted as establishing the superiority of fibrinogen concentrate for intraoperative bleeding management. [2]

A 2025 systematic review and meta-analysis evaluated fibrinogen concentrate versus cryoprecipitate for acquired hypofibrinogenemia in cardiac surgery, including 4 RCTs with 945 participants (823 adults and 122 children). Three fibrinogen concentrate products were evaluated: Fibryga (2 RCTs), RiaSTAP (1 RCT), and Haemocomplettan P (1 RCT). Across the pooled studies, fibrinogen concentrate was not associated with significant differences compared with cryoprecipitate in postoperative mortality (RR 1.25; 95% CI 0.79 to 1.96), blood loss (standardized mean difference [SMD] -0.14; 95% CI -0.46 to 0.18), or transfusion rates of red blood cells (RR 0.98; 95% CI 0.77 to 1.26), platelets (RR 0.17; 95% CI 0.02 to 1.40), fresh frozen plasma (RR 0.48; 95% CI 0.16 to 1.45), or cryoprecipitate (RR 1.02; 95% CI 0.58 to 1.81). No significant differences were identified in infection, volume overload, transfusion reactions, or postoperative thrombosis, and no allergic reactions were reported. Exploratory analyses also found no significant differences in duration of mechanical ventilation, intensive care unit stay, or hospitalization. However, these findings reflect pooled results across different fibrinogen concentrates and do not establish Fibryga-specific comparative effectiveness. Additionally, the analysis did not discuss differences in intraoperative factor utilization, cost savings, or operating room time. Overall, the evidence suggests comparable clinical outcomes between fibrinogen concentrate and cryoprecipitate for correcting hypofibrinogenemia in cardiac surgery, but certainty was moderate for mortality and low for other outcomes; pediatric findings were particularly limited by small sample sizes and substantial heterogeneity. [3]

Background References: [1] Tibi P, McClure RS, Huang J, et al. STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. Ann Thorac Surg. 2021;112(3):981-1004. doi:10.1016/j.athoracsur.2021.03.033
[2] Casselman FPA, Lance MD, Ahmed A, et al. 2024 EACTS/EACTAIC Guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP. Eur J Cardiothorac Surg. 2025;67(5):ezae352. doi:10.1093/ejcts/ezae352
[3] Chen Y, Yang W, Zhao C, et al. Treatment effects of fibrinogen concentrates vs. cryoprecipitate for correcting hypofibrinogenemia in cardiac surgery patients: a systematic review and meta-analysis. Front Cardiovasc Med. 2025;12:1671405. Published 2025 Oct 17. doi:10.3389/fcvm.2025.1671405
Literature Review

A search of the published medical literature revealed 6 studies investigating the researchable question:

Please provide a data summary for the use of Fibryga in cardiac surgery for use by anesthesia during the procedure as an alternative to cryoprecipitate or IFC in terms of clinical outcomes for differences in factor utilization, cost savings, LOS, time in OR, and bleeding outcomes

Level of evidence

B - One high-quality study or multiple studies with limitations  Read more→



Please see Tables 1-6 for your response.


 

Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery
Design

Randomized clinical trial at 11 Canadian hospitals; The FIBRES Randomized Clinical Trial

N= 827

Objective To determine if fibrinogen concentrate is noninferior to cryoprecipitate for treatment of bleeding related to hypofibrinogenemia after cardiac surgery
Study Groups

Fibrinogen concentrate (n= 372)

Cryoprecipitate (n= 363)

Inclusion Criteria Adult patients experiencing clinically significant bleeding and hypofibrinogenemia after cardiac surgery
Exclusion Criteria Receipt of fibrinogen concentrate or cryoprecipitate within 24 hours before surgery; history of severe allergic reaction to fibrinogen concentrate or cryoprecipitate; refusal of blood components for religious or other reasons; plasma fibrinogen level greater than 3.0 g/L within 30 minutes of treatment order; known pregnancy
Methods

Participants were randomly assigned to receive either 4 g of fibrinogen concentrate or 10 units of cryoprecipitate within 24 hours after cardiopulmonary bypass. The primary outcome was the number of blood components (red blood cells, platelets, plasma) administered during 24 hours post bypass. A 2-sample, 1-sided test for the ratio of the mean number of units was conducted to evaluate noninferiority.

Duration February 10, 2017, to November 1, 2018
Outcome Measures

Primary: Blood components administered during 24 hours post bypass

Secondary: Thromboembolic events

Baseline Characteristics   Fibrinogen Concentrate (n= 372) Cryoprecipitate (n= 363)
Age, median (IQR), y 65 (54-72) 64 (53-72)
Sex - Women 113 (30.4%) 105 (28.9%)
Sex - Men 259 (69.6%) 258 (71.1%)
Race - White 287 (77.2%) 273 (75.2%)
Race - Asian 51 (13.7%) 58 (16.0%)
Body mass index, kg/m2, median (IQR) 22.2 (19.6-25.4) 22.8 (19.6-25.6)
Results   Fibrinogen Concentrate (n= 372) Cryoprecipitate (n= 363) p-value
Mean 24-hour postbypass allogeneic transfusions, units (95% confidence interval [CI]) 16.3 (14.9 to 17.8)

17.0 (15.6 to 18.6)

< 0.001
Thromboembolic events 26 (7.0%)

35 (9.6%)

 
Adverse Events

Overall, treatment-emergent adverse events were similar between groups. Death rates were not statistically significant (9.4% fibrinogen vs 7.4% cryoprecipitate; p= 0.35) even when stratifying by critical state prior to surgery.

Study Author Conclusions

In patients undergoing cardiac surgery who develop clinically significant bleeding and hypofibrinogenemia after cardiopulmonary bypass, fibrinogen concentrate is noninferior to cryoprecipitate with regard to number of blood components transfused in a 24-hour period post bypass. Use of fibrinogen concentrate may be considered for management of bleeding in patients with acquired hypofibrinogenemia in cardiac surgery.

Critique

The study was well-designed with a large sample size and multicenter approach, enhancing its generalizability. However, the lack of blinding for clinicians involved in product administration could introduce bias. The study's pragmatic design did not standardize transfusion protocols across sites, which might affect the consistency of results. Additionally, the study was limited to cardiac surgery patients, which may not make the findings applicable to other clinical settings requiring fibrinogen replacement.

 

Table 1 References:
[4] Callum J, Farkouh ME, Scales DC, et al. Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial. JAMA. 2019;322(20):1966-1976. doi:10.1001/jama.2019.17312

 

Prospective, Randomized Study of Fibrinogen Concentrate Versus Cryoprecipitate for Correcting Hypofibrinogenemia in Cardiac Surgery Patients

Design

Single-center, prospective, randomized study

N= 88

Objective

To compare cryoprecipitate and fibrinogen concentrate (FC) for the correction of acquired hypofibrinogenemia and the associated costs

Study Groups

Cryoprecipitate (n= 40)

Fibrinogen Concentrate (FC), Fibryga (n= 48)

Inclusion Criteria

Participants who underwent CPB from 2021 to 2022 and developed clinically significant bleeding and hypofibrinogenemia

Exclusion Criteria

Patients who had received fibrinogen-containing products within 24 hours before surgery, history of severe allergic reaction to cryoprecipitate or FC, refusal of FC or cryoprecipitate due to religious or other reasons

Methods

Patients in the first group received FC (Fibryga), whereas those in the second group were treated with cryoprecipitate. Cryoprecipitate group received 1 unit per 5-10 kg body weight. FC group received doses calculated using a formula with a target fibrinogen level of 2.0 g/L. Fibrinogen levels were assessed preoperatively, postoperatively, and at 24 and 48 hours after administration.

Duration

2021 to 2022

Outcome Measures

Primary: Direct treatment cost

Secondary: Change in fibrinogen level after FC and/or cryoprecipitate dosing

Baseline Characteristics

Characteristic

Cryoprecipitate Group (n= 40) Fibrinogen Concentrate (FC), Fibryga (n= 48)

Age, years, median (range)

59 (29 to 77) 58 (21 to 81)

Female

21 (52.5%) 19 (39.9%)

Weight, kg

70.5 (24 to 96) 69.5 (46 to 118)

BMI, kg/m2

26.6 (9.5 to 34.2) 26.4 (16.7 to 37.5)

BSA, m2

1.8 (1.0 to 2.2) 1.8 (1.5 to 2.4)

Stroke

10 (25.0%) 9 (18.8%)

MI

19 (47.5%) 16 (33.0%)

Diabetes

11 (27.5%) 14 (29.0%)

Type of surgery

Bentall-de Bono

CABG

HM3 LVAD

HTX

Valve surgery

 

6 (15.0%)

12 (30.0%)

2 (5.0%)

1 (2.5%)

18 (45.0%)

 

5 (10.4%)

16 (33.3%)

2 (4.2%)

2 (4.2%)

20 (41.7%)

Abbreviations: BMI, body mass index; BSA, body surface area; MI, myocardial infarction

Results Outcome Cryoprecipitate Group (n= 40) Fibrinogen Concentrate (FC), Fibryga (n= 48) p-value (Equal Variances)

Mean cost per patient

$1,505.06 ± $152.40 $631.75 ± $223.67 p< 0.0001

Change in Plasma Fibrinogen Levels

Preoperative, mean ± SD, mg/dL

Pre-treatment, mean ± SD, mg/dL

24 h after treatment, mean ± SD, mg/dL

48 h after treatment, mean ± SD, mg/dL

 

289 ± 72

165 ± 19

288 ± 74

410 ± 143

 

260 ± 64

152 ± 29

247 ± 59

390 ± 160

 

0.0511

0.0288

0.0043

0.4450

The study provided both equal and unequal p-value variances but the table only includes the former. 

Adverse Events

No adverse reactions or adverse events related to treatment were recorded in patients in either group.

Study Author Conclusions

Analysis of plasma fibrinogen concentration showed that cryoprecipitate and FC had comparable effectiveness. However, FC is advantageous over cryoprecipitate due to its ease of handling, lower cost, and high purity.

Critique

The study's strengths include its prospective, randomized design and direct comparison of cryoprecipitate and FC. However, limitations include the inability to administer equivalent fibrinogen doses for both treatments due to established protocols, and the cost analysis only assessed direct costs, which may vary across institutions and countries.

 
Table 2 References:
[5] Ayaganov D, Kuanyshbek A, Vakhrushev I, Li T. Prospective, Randomized Study of Fibrinogen Concentrate Versus Cryoprecipitate for Correcting Hypofibrinogenemia in Cardiac Surgery Patients. Journal of Cardiothoracic and Vascular Anesthesia. 2024;38(1):80-85. doi:https://doi.org/10.1053/j.jvca.2023.10.031

 

A Comparison of the In Vitro Effects of Three Fibrinogen Concentrates on Clot Strength in Blood Samples from Cardiacsurgery Patients

Design

Prospective, in vitro study

N= 23

Objective

To compare the efficacy of three fibrinogen concentrates (Fibclot, Fibryga, Riastap) in restoring clot strength in blood samples from cardiac surgery patients

Study Groups

Fibclot (n= 23)

Fibryga (n= 23)

Riastap (n= 23)

Placebo (n= 23)

Inclusion Criteria

Patients >18 years undergoing cardiac surgery with a preoperative fibrinogen concentration of ≤3.6 g/L

Exclusion Criteria

Patients with a known bleeding disorder or severe renal or hepatic disease

Methods

Blood samples were collected postoperatively from cardiac surgery (cardiopulmonary bypass) patients and were divided into 4 vials with 1.124 mg of one of three fibrinogen concentrates, including Riastap, Fibryga, Fibclot or placebo. A total of 300 mcL of each blood sample was combined with a fibrinogen concentrate sample. Fibrinogen dose corresponded to 2.5 g per 70 kg of body weight. Clot strength was assessed and compared between the samples using the ROTEM extrinsic thromboelastometry (EXTEM) and fibrinogen-specific thromboelastometry (FIBTEM) on all samples. EXTEM used tissue factor activation to initiate clot formation; while FIBTEM used tissue factor, cytochalasin D, an actin polymerization inhibitor to irreversibly eliminate the platelets' contribution to clot formation (independent of platelets). Both clot formation time (CFT) and maximum clot firmness (MCF) were reported for EXTEM, while only MCF was reported for FIBTEM.

Duration

October 2018 to November 2018

Outcome Measures

Clot strength, time to clot formation, and clot firmness before and after supplementation with fibrinogen concentrates

Baseline Characteristics

 

All patients (N= 23)

 

     

Age, years

66 (60-75)        

Male

83%        

Procedure

Coronary artery bypass grafting

Aortic valve surgery

Mitral valve surgery

 

43%

48%

0.9%

       

Body mass index, kg/m2

26.6 (24.7-30.7)        

Cardiopulmonary bypass time, min

73 (64-90)        

Aortic clamp time, min

52 (49-79)        

Postoperative bleeding, mL

300 (200-600)        

Results

Endpoint

Placebo (n= 23)

Fibryga (n= 23)

Fibclot (n= 23)

Riastap (n= 23)

p-value

FIBTEM MCF, mm

11.5 (10–14)  14.5 (12–17)a 17 (14.5–20)a,b 15.5 (12–18)a <0.001 

EXTEM MCF, mm

57 (51.5–60)  60 (55.5–63.5)a,c 61 (57–64)a,b 58.5 (54–61.5)a <0.001

EXTEM CFT, s

99 (87–131.5) 92.5 (82.5–119)a 80 (74–106.5)a,b 96.5 (80–118.5)d <0.001 

Abbreviations: FIBTEM, fibrinogen-specific thromboelastometry; EXTEM, ROTEM extrinsic thromboelastometry; CFT, clot formation time; CT, clotting time; MCF, maximum clot firmness

FIBTEM: All fibrinogen concentrates increased maximum clot firmness with FIBTEM, compared to placebo. FIBTEM MCF with Fibclot increased (+46% [25th–75th percentile 35–55] compared to placebo) significantly more than with Fibryga (+26% [21–35]) and Riastap (+29% [22–47], p< 0.001). No difference was found between Fibryga and Riastap (p= 0.25).

EXTEM: All fibrinogen concentrates, compared to placebo, increased EXTEM MCF and decresed EXTEM CFT.  Fibclot increased EXTEM MCF (+7.2% [3.0–9.0] vs. placebo) significantly more than did both Fibryga (+5.1% [3.0–7.5]) and Riastap supplementation (+3.5% [1.5–6.0], both p< .001 vs. Fibclot). Fibclot shortened EXTEM CFT (−18% [−13 to −25]) more than Fibryga (−6.1% [−2.0 to −8.0]) and Riastap (−5.2% [−0.0 to −9.0], p< .001 for both vs. Fibclot). A significant difference was found between Fibryga and Riastap for EXTEM MCF (p< 0.001), but no difference was found for EXTEM CFT (p= 0.68). 

ap< 0.001 versus placebo

bp< 0.001 versus Fibryga and Riastap

cp< 0.001 versus Riastap

dp= 0.003 versus placebo

Adverse Events

Not discussed

Study Author Conclusions

At the selected dose, Fibclot was more effective than Fibryga and Riastap in restoring clot strength, shortening clot formation time, and increaseing maximum clot firmness in postoperative blood samples from cardiac surgery patients. These results may have implications for the choice of fibrinogen concentrate and dosing.

InpharmD Researcher Critique

Limitations include small sample size, niche cardiac study population, and short duration of study. Due to the design and study population, this study's dosing and results may not be extended to the general population. While results of this in-vitro study were significant, clinical significance cannot be concluded based on the results.

 
Table 3 References:
[6] Stolt H, Shams Hakimi C, Singh S, Jeppsson A, Karlsson M. A comparison of the in vitro effects of three fibrinogen concentrates on clot strength in blood samples from cardiac surgery patients. Acta Anaesthesiol Scand. 2021;65(10):1439-1446. doi:10.1111/aas.13967

 

Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery
Design

Randomized, placebo-controlled, double-blind clinical trial

N=120

Objective To determine whether fibrinogen concentrate infusion dosed to achieve a plasma fibrinogen level of 2.5 g/L in high-risk cardiac surgery patients with intraoperative bleeding reduces intraoperative blood loss
Study Groups

Fibrinogen concentrate (n=60)

Placebo (n=60)

Inclusion Criteria Patients undergoing elective, high-risk cardiac surgery with intraoperative bleeding (blood volume between 60 and 250 mL suctioned from the thoracic cavity in a period of 5 minutes)
Exclusion Criteria Proof or suspicion of a congenital or acquired coagulation disorder, any stroke or myocardial infarction within 2 months preceding surgery, venous or arterial thrombosis, clopidogrel use in the 5 days preceding surgery, glycoprotein IIb/IIIa receptor antagonist use in the 2 days preceding surgery, or INR of more than 1.4 in patients who used coumarins
Methods Intravenous, single-dose administration of fibrinogen concentrate or placebo, targeted to achieve a postinfusion plasma fibrinogen level of 2.5 g/L. Blood loss was measured between intervention and closure of chest. Safety variables were monitored within 30 days
Duration February 2011 to January 2015
Outcome Measures Primary: Blood loss in milliliters between intervention and closure of chest Secondary: Measured blood loss 1, 3, 6, 12, and 24 hours after intervention, proportion of patients who had received a transfusion, number of units of blood products used, adverse events within 30 days
Baseline Characteristics   Fibrinogen (n= 60) Control (n= 60)
Age, mean (SD), y 70 (10) 72 (10)
Women, No. (%) 21 (35) 16 (27)
Body surface area, mean (SD), m2 1.96 (0.19) 1.99 (0.22)
EuroSCORE, mean (SD) 7 (3) 7 (2)
Diabetes type 1 or 2, No. (%) 16 (27) 19 (32)
Hypertension, No. (%) 38 (63) 41 (68)
Left ventricular hypertrophy, No. (%) 27 (45) 32 (53)
Preoperative use of anticoagulants - Aspirin, No. (%) 31 (52) 33 (55)
Preoperative use of anticoagulants - Clopidogrel, No. (%) 0 (0) 1 (2)
Preoperative use of anticoagulants - Nadroparin, No. (%) 8 (13) 6 (10)
Preoperative use of anticoagulants - Coumarins, No. (%) 16 (27) 10 (17)
Left ventricular ejection fraction %, No. (%) - <30 9 (15) 5 (8)
Left ventricular ejection fraction %, No. (%) - 30-50 18 (30) 10 (17)
Left ventricular ejection fraction %, No. (%) - >50 33 (55) 45 (75)
Previous cardiac surgery, No. (%) 5 (8) 4 (7)
Type of surgery - CABG surgery and valve(s), No. (%) 43 (72) 43 (72)
Type of surgery - Valves only, No. (%) 6 (10) 7 (11)
Type of surgery - Thoracic aorta surgery, No. (%) 11 (18) 10 (17)
Results   Fibrinogen (n= 58) Control (n= 57) p-value
Blood loss between intervention and chest closure, median (IQR), mL 50 (29-100) 70 (33-145) 0.19
Cumulative 24-h blood loss, median (IQR), mL 570 (390-730) 690 (400-1090) 0.047

SD= standard deviation; IQR= nterquartile range

The study was not adequately powered to formally evaluate secondary outcomes, including additional procoagulant or antifibrinolytic use and adverse events. Postoperatively, 1 patient (2%) in the fibrinogen concentrate group and 6 patients (10%) in the control group received additional fibrinogen concentrate. Tranexamic acid was administered to 9 patients (15%) in the fibrinogen group and 15 patients (25%) in the control group, while prothrombin complex concentrate was given to 4 patients (7%) in the fibrinogen group and 10 patients (17%) in the control group. Although the trial reported more adverse events in the fibrinogen group, including 4 strokes, the limited sample size and low event rates precluded definitive conclusions about safety.

Adverse Events

There were more adverse events in the fibrinogen group: 4 strokes or transient ischemic attacks in fibrinogen patients and 2 in the control patients, 3 myocardial infarctions in the fibrinogen patients compared with 1 in the control patients, and 2 mortalities in the fibrinogen group but none in the control patients.

Study Author Conclusions

Among patients with intraoperative bleeding during high-risk cardiac surgery, administration of fibrinogen concentrate, compared with placebo, resulted in no significant difference in the amount of intraoperative blood loss.

Critique

The study was well-designed as a randomized, placebo-controlled, double-blind clinical trial, which strengthens the validity of the findings. However, the study was limited by its single-center design, which may affect the generalizability of the results. Additionally, despite randomization, there were baseline differences between groups, and the study was not powered to detect differences in adverse events, which were more frequent in the fibrinogen group. The observed bleeding was less than expected, which may have impacted the ability to detect a significant difference in the primary outcome.

Table 4 References:
[7] Bilecen S, de Groot JA, Kalkman CJ, et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial. JAMA. 2017;317(7):738-747. doi:10.1001/jama.2016.21037

 

Fibrinogen concentrate reduces intraoperative bleeding when used as first-line hemostatic therapy during major aortic replacement surgery: Results from a randomized, placebo-controlled trial
Design

Single-center, prospective, double-blind, randomized, placebo-controlled trial

N= 61

Objective To assess whether fibrinogen concentrate as targeted first-line hemostatic therapy was more effective than placebo or a standardized transfusion algorithm in controlling coagulopathic bleeding in patients undergoing major aortic surgery
Study Groups

Fibrinogen concentrate (n= 29)

Placebo (n= 32)

Inclusion Criteria Patients aged 18 years or more undergoing elective thoracic or thoracoabdominal aortic replacement surgery with cardiopulmonary bypass, exhibiting clinically relevant bleeding before administration of fibrinogen concentrate or placebo
Exclusion Criteria Patients with congenital or acquired coagulation disorders, previous surgery at the same site, stroke or myocardial infarction within 2 months before surgery, and use of aspirin, clopidogrel, or vitamin K antagonists within 2 to 5 days before surgery
Methods Patients were randomized to receive either fibrinogen concentrate or placebo if they exhibited clinically relevant coagulopathic bleeding after cardiopulmonary bypass removal. Fibrinogen concentrate dosing was individualized using the thromboelastometric FIBTEM test. If bleeding continued, a standardized transfusion algorithm was followed. The change in bleeding rate after treatment was compared using t-tests
Duration June 2008 to April 2010
Outcome Measures

Change in bleeding rate after treatment

Baseline Characteristics   Fibrinogen concentrate (n= 29) Placebo (n= 32)
Male 66% 78%
Mean age, years 59 61
Weight, kg 88 87
Body mass index, kg/m2 28 28
Obesity 24% 22%
Results

Placebo

  • In the placebo group, all 32 patients received one cycle of transfusion consisting of 4 units of fresh-frozen plasma (FFP) or 2 units of platelet concentrate. The baseline rate of bleeding immediately before transfusion was 122 ± 55 g per 5 minutes, which was comparable to the rate observed before placebo infusion. After a single cycle of transfusion, the rate of coagulopathic bleeding decreased by 16 g per 5 minutes, equivalent to approximately 180 mL per hour. This reduction was statistically significant compared with placebo (p= 0.004), demonstrating a measurable hemostatic effect of one cycle of FFP or platelet transfusion.

Hemostatic Effects of 2 Cycles of Transfusion (FFP and Platelets) Versus Placebo

  • Of the 32 patients in the placebo group, 30 received a second transfusion cycle, receiving whichever therapy was not administered in the first cycle. As a result, all 30 patients undergoing two cycles received a total of 4 units FFP plus 2 units of platelets. After these two cycles, the rate of bleeding decreased by 28 g per 5 minutes, equivalent to approximately 320 mL per hour. This reduction was also statistically significant compared with placebo (p= 0.002), indicating that a second transfusion cycle provided an additive hemostatic benefit over a single cycle.

Fibrinogen Concentrate Versus 1 Cycle of Transfusion

  • Although one cycle of FFP or platelet transfusion had a positive effect on hemostasis, the reduction in bleeding observed after transfusion was significantly less than the reduction achieved with fibrinogen concentrate infusion. Statistical analysis confirmed that fibrinogen concentrate produced a superior decrease in the rate of bleeding compared with a single cycle of FFP or platelets (p= 0.003), highlighting the potent hemostatic effect of fibrinogen concentrate in this setting.

Fibrinogen Concentrate Versus 2 Cycles of Transfusion

  • When compared with two cycles of FFP and platelet transfusion, which reduced bleeding by 28 g per 5 minutes (320 mL per hour), fibrinogen concentrate decreased bleeding by 48 g per 5 minutes (550 mL per hour). Although this reduction was greater than that observed with two cycles of standard transfusion, the difference did not reach statistical significance (p= 0.11). These results suggest a trend toward superior efficacy of fibrinogen concentrate over combined transfusion of FFP and platelets, but the evidence was not definitive.
Adverse Events Not specifically detailed
Study Author Conclusions

FIBTEM-guided intraoperative hemostatic therapy with fibrinogen concentrate is more effective than placebo in controlling coagulopathic bleeding during major aortic replacement surgery. Fibrinogen concentrate is also more effective than 1 cycle of fresh-frozen plasma/platelets and is more rapid than, and at least as effective as, 2 cycles of fresh-frozen plasma/platelets.

Critique

The study provides strong evidence for the efficacy of fibrinogen concentrate in reducing intraoperative bleeding compared to placebo and transfusion cycles. However, the single-center design and the specific patient population may limit the generalizability of the findings. Additionally, the study did not detail adverse events, which are crucial for assessing the safety profile of fibrinogen concentrate.

Table 5 References:
[8] Rahe-Meyer N, Hanke A, Schmidt DS, Hagl C, Pichlmaier M. Fibrinogen concentrate reduces intraoperative bleeding when used as first-line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo-controlled trial. J Thorac Cardiovasc Surg. 2013;145(3 Suppl):S178-S185. doi:10.1016/j.jtcvs.2012.12.083
Cost-effectiveness of Fibrinogen Concentrate vs Cryoprecipitate for Treating Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients
Design

Within-trial economic evaluation of the FIBRES randomized clinical trial (the trial summarized in Table 1)

N= 495

Objective To determine cost-effectiveness of fibrinogen concentrate vs cryoprecipitate for managing active bleeding in adult patients who underwent cardiac surgery
Study Groups

Fibrinogen concentrate (n= 251)

Cryoprecipitate (n= 244)

Inclusion Criteria Adult patients from the FIBRES trial who underwent cardiac surgery and developed active bleeding and acquired hypofibrinogenemia requiring fibrinogen replacement
Exclusion Criteria Patients who were critically ill before surgery were excluded from certain analyses due to substantial variability in costs
Methods

A patient-level, bottom-up costing approach was used to compare fibrinogen concentrate (FC) with cryoprecipitate among patients enrolled in the FIBRES trial. Cost data were requested from the finance departments of all participating Ontario hospitals and calculated using the standardized Management Information Systems Patient Costing Methodology, an activity-based costing approach. Per-patient hospital costs were collected for up to 28 days after surgery and included both direct costs (fixed and variable costs associated with service recipients and nonservice recipients) and indirect costs (eg, administrative and systems support services). Costs were categorized by resource utilization, including operating room (OR), intensive care unit (ICU), nursing, and pharmacy.

Blood product costs included the initial FC or cryoprecipitate treatment, as well as subsequent use of allogeneic blood products (ABPs), recombinant factor VIIa (rFVIIa), and prothrombin complex concentrate (PCC) through 7 days after cardiopulmonary bypass (CPB). Unit costs were obtained from Canadian Blood Services. Product wastage was incorporated by applying cost adjustments based on the proportion of unused, returned, or discarded products: 1.02 for red blood cells (RBCs), 1.19 for platelets, 1.07 for plasma, and 1.07 for cryoprecipitate. Exploratory analyses examined variation in total costs across treatment sites and predefined patient subgroups.

Baseline characteristics between treatment groups were assessed using standardized mean differences (SMDs), with values greater than 0.1 considered indicative of imbalance. ABP utilization was compared using the Wilcoxon rank-sum test. Mean costs were calculated for each resource utilization category and compared between treatment groups; differences in mean costs and corresponding 95% confidence intervals (CIs) were estimated using 10,000 bootstrap replicates.

Cost-effectiveness was evaluated using incremental net monetary benefit (INB) and net benefit regression (NBR). INB was calculated by subtracting the incremental cost of FC relative to cryoprecipitate from the incremental clinical benefit, expressed as the reduction in ABP use multiplied by the decision maker's willingness-to-pay (WTP) for each unit reduction in ABP use. Because an established WTP threshold was unavailable, the analysis evaluated values ranging from CAD $0 to $3,000 (approximately USD $2,234). FC was considered cost-effective compared with cryoprecipitate when the INB was greater than zero at the specified WTP threshold.

An adjusted NBR model was also developed to evaluate the influence of treatment group, hospital site, baseline covariates with SMD greater than 0.1, and predefined subgroup characteristics. The model included interaction terms between treatment group and subgroup to assess whether cost-effectiveness differed by patient population. The two predefined subgroup comparisons were preoperative critical versus noncritical illness and elective versus non-elective surgery. Critical preoperative illness was determined through blinded adjudication and included emergency surgery with ventricular tachycardia/fibrillation or cardiac arrest, preoperative cardiac massage, ventilation, inotrope or ventricular assist device use, acute kidney failure (anuria or oliguria less than 10 mL/hour), or acute aortic dissection. Finally, cost-effectiveness acceptability curves were generated to characterize the probability that FC was cost-effective across the range of WTP thresholds.

Duration

February 2017 to November 2018

Outcome Measures

Primary: Number of allogeneic blood products (ABPs) administered within 7 days post-cardiopulmonary bypass

Secondary: ABPs administered within 24 hours of cardiopulmonary bypass, in-hospital resource utilization costs within 28 days

Baseline Characteristics   Fibrinogen concentrate (n= 251) Cryoprecipitate (n= 244)
Age, mean (SD), years 59.2 (15.4) 59.4 (15.8)
Male 174 (69.3%) 170 (69.7%)
Critically ill before surgery 37 (14.7%) 17 (7.0%)
Results

Effectiveness and blood product utilization: Approximately 90% of ABP transfusions occurred within 24 hours after cardiopulmonary bypass (CPB). Median cumulative ABP use was lower with FC than cryoprecipitate at 24 hours (9 vs. 12 units; p= 0.03), but the difference was not statistically significant at 7 days (10 vs. 13 units; p= 0.06). Platelet use was lower with FC at both 24 hours (8 vs 8 units; p= 0.02) and 7 days (8 vs. 8 units; p= 0.02), although median values were the same and mean utilization differed. Red blood cell and plasma transfusion requirements did not differ significantly. Use of prothrombin complex concentrate and recombinant factor VIIa was also similar. Adverse events, severe or massive bleeding, and deaths were comparable at 28 days, with no significant differences in ICU stay, mechanical ventilation duration, or hospitalization.

Costs and resource utilization: Median 7-day ABP costs were CAD $2,280 with FC versus CAD $2,770 with cryoprecipitate. Median total 28-day costs, including treatment, ABP transfusions, and hospital resource utilization, were similar (CAD $38,180 vs. CAD $38,790). Hospital resource utilization accounted for approximately 93% of total costs, primarily ICU (36%), OR (26%), and nursing (9%) costs. Although mean total costs were numerically higher with FC (CAD $60,780 vs. CAD $59,200), the difference was highly variable and the 95% confidence interval crossed zero. Subgroup analyses also showed substantial cost variability, particularly among critically ill and nonelective patients.

Cost-effectiveness: In unadjusted analyses, FC was associated with a mean incremental cost of CAD $1,580 and a mean reduction of 0.9 ABP units compared with cryoprecipitate. Results differed by preoperative illness severity. Among noncritically ill patients, FC was associated with lower mean costs (incremental cost, −CAD $3,030) and lower ABP use (3.3 fewer units); 73% of bootstrap estimates indicated that FC was both less costly and more effective. In adjusted analyses, the probability that FC was cost-effective among noncritically ill patients was 86% at a WTP of CAD $0 per ABP unit avoided and 97% at CAD $2,000. FC was also likely cost-effective among elective surgery patients (86% and 97%, respectively), but results were uncertain among nonelective patients (47% and 41%). Estimates among critically ill patients were imprecise because of the small subgroup and substantial cost variability.

Adverse Events

Adverse events were similar in both treatment groups, with no significant differences in ICU stay, duration of mechanical ventilation, or hospitalization.

Study Author Conclusions

Fibrinogen concentrate is cost-effective when compared with cryoprecipitate in most bleeding adult patients who underwent cardiac surgery with acquired hypofibrinogenemia requiring fibrinogen replacement. The generalizability of these findings outside the Canadian health system needs to be verified.

Critique

The study provides valuable insights into the cost-effectiveness of fibrinogen concentrate versus cryoprecipitate, with a robust within-trial economic evaluation. However, the generalizability of the findings may be limited due to the study's focus on the Canadian health system and the exclusion of critically ill patients from certain analyses, which may affect the applicability of the results to other settings or populations.

Table 6 References:
[9] Abrahamyan L, Tomlinson G, Callum J, et al. Cost-effectiveness of Fibrinogen Concentrate vs Cryoprecipitate for Treating Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients. JAMA Surg. 2023;158(3):245-253. doi:10.1001/jamasurg.2022.6818